A Long-term Follow-up Study of Patients Who Received VOR33 is a registry-stage clinical asset sponsored by Vor Biopharma in Leukemia, Myeloid, Acute. SEO and diligence focus: VOR33, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.